Boehringer Ingelheim and Eli Lilly strengthen their position in the Korean heart failure treatment market with new indications for Jardiance (ingredient: empagliflozin), a sodium-glucose co-transporter 2 (SGLT-2) inhibitor drug.

Professor Choi Seung-hoon from Kangnam Sacred Heart Hospital at Hallym University explains the importance of Jardiance’s new indications for treating heart failure at an online press conference Friday.

Jardiance was instrumental in expanding the area of ​​treatment for SGLT2 inhibitors from diabetes to heart failure based on the results of the EMPEROR-Reduced clinical study presented at the European Society of Cardiology (ESC) 2021.

The companies confirmed that Jardiance reduced the risk of heart failure hospitalization and death from cardiovascular disease by 25% in heart failure patients treated with standard therapy compared to the placebo group.

The treatment also reduced the risk of hospitalization for first-time heart failure, which was the secondary endpoint, by 31% and the incidence of kidney complications by 50%.

Based on these results, on November 23, the Ministry of Food and Pharmaceutical Safety granted an additional indication to Jardiance in the treatment of patients with chronic heart failure with reduced left ventricular systolic function.

Doctors welcomed the new indication for Jardiance.

“Among patients with heart failure, drug treatment is difficult in patients with kidney failure,” Prof. Choi Seung-hoon from Hallym University’s Sacred Heart Hospital in Kangnam said at the meeting. ‘a press conference on Friday. “In the subsection of the EMPEROR-Reduced study, the company confirmed the protective effect on kidney function of Jardiance regardless of existing drugs.”

Choi pointed out that hospitals often have to stop mineralocorticoid receptor antagonists (MRAs), one of the most important drugs in the treatment of heart failure, in the middle of treatment for a variety of reasons.

“However, SGLT-2 inhibitors also reduced ARM discontinuation,” Choi said. “As a result, we can use Jardiance in patients with heart failure accompanied by kidney disease, and this reduces the need to interrupt or add therapy by maintaining existing standard therapy for a long time. “

Noting that many patients complain of uncomfortable symptoms, Professor Choi reported that Jardiance improved the quality of life in three months and maintained the effects.

Choi also pointed out that the drug’s data on Asians was also important.

“About 18 percent of the study subjects were Asians, including 93 Korean patients,” Choi said. “It is significant that safety and efficacy have been confirmed in Asians, especially Koreans. “

Choi stressed that the government should reimburse the drug as soon as possible to help doctors use the treatment.

“Despite two large-scale clinical trials related to SGLT-2 inhibitors in heart failure with reduced cardiac output, the government has yet to reimburse treatment,” Choi said. “Considering that the number of heart failure patients is increasing rapidly in Korea, I hope that reimbursement will be available soon. “